Denise L. Cecil

776 total citations
29 papers, 621 citations indexed

About

Denise L. Cecil is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Denise L. Cecil has authored 29 papers receiving a total of 621 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Immunology, 14 papers in Molecular Biology and 13 papers in Oncology. Recurrent topics in Denise L. Cecil's work include Immunotherapy and Immune Responses (19 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Cancer Research and Treatments (7 papers). Denise L. Cecil is often cited by papers focused on Immunotherapy and Immune Responses (19 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Cancer Research and Treatments (7 papers). Denise L. Cecil collaborates with scholars based in United States, South Korea and Netherlands. Denise L. Cecil's co-authors include Robert Terkeltaub, Mary L. Disis, Ann Marie Schmidt, Ekram Gad, Kristen Johnson, John Rediske, Martin Lotz, Kyong Hwa Park, Ru Liu‐Bryan and David M. Rose and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

Denise L. Cecil

27 papers receiving 611 citations

Peers

Countries citing papers authored by Denise L. Cecil

Since Specialization

Citations

This map shows the geographic impact of Denise L. Cecil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denise L. Cecil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denise L. Cecil more than expected).

Fields of papers citing papers by Denise L. Cecil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denise L. Cecil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denise L. Cecil. The network helps show where Denise L. Cecil may publish in the future.

Co-authorship network of co-authors of Denise L. Cecil

This figure shows the co-authorship network connecting the top 25 collaborators of Denise L. Cecil. A scholar is included among the top collaborators of Denise L. Cecil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denise L. Cecil. Denise L. Cecil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Vaccines for breast cancer prevention: Are we there yet? 2024 ·Molecular Aspects of Medicine ·Shaveta Vinayak, Denise L. Cecil, Mary L. Disis	2
2	Abstract 6434: A precision probiotic therapeutic promotes a more efficacious type I immune response and limits breast cancer growth in mice 2023 ·Cancer Research ·Denise L. Cecil, (unknown), (unknown), (unknown), David N. Fredricks, Mary L. Disis	1
3	546 A phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer 2022 ·Regular and Young Investigator Award Abstracts ·Mary L. Disis, Ying Liu, Sasha E. Stanton, William R. Gwin, Andrew L. Coveler, John B. Liao, Jennifer S. Childs, Denise L. Cecil	10
4	Unexpected Liver and Kidney Pathology in C57BL/6J Mice Fed a High-fat Diet and Given Azoxymethane to Induce Colon Cancer 2022 ·Comparative Medicine ·Kimberly S. Waggie, (unknown), Denise L. Cecil, (unknown), (unknown), Mary L. Disis	0
5	Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer 2022 ·Scientific Reports ·Denise L. Cecil, (unknown), Ekram Gad, Michael Gormley, Andrew E. Timms, (unknown), Rinke Bos, Rajendra N. Damle, Manuel A. Sepúlveda, Mary L. Disis	3
6	1176 Optimizing immunization schedules for therapeutic vaccination 2022 ·Regular and Young Investigator Award Abstracts ·Yushe Dang, Denise L. Cecil, (unknown), (unknown), Mary L. Disis	1
7	Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses 2021 ·Clinical Cancer Research ·Denise L. Cecil, John B. Liao, Yushe Dang, Andrew L. Coveler, Angela Shaulov Kask, Yi Yang, Jennifer S. Childs, Doreen M. Higgins, Mary L. Disis	11
8	Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention 2021 ·Frontiers in Immunology ·(unknown), Denise L. Cecil, Ekram Gad, (unknown), Andrew L. Coveler, Jennifer S. Childs, Ronald A. Lubet, Mary L. Disis	21
9	Breast cancer vaccines for treatment and prevention 2021 ·Breast Cancer Research and Treatment ·Mary L. Disis, Denise L. Cecil	17
10	Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers 2020 ·Molecular Cancer Therapeutics ·Mary L. Disis, (unknown), Ekram Gad, (unknown), Denise L. Cecil, Peter D. Senter, Shyra J. Gardai, Nicole M. Okeley	15
11	Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo 2016 ·Clinical Cancer Research ·Denise L. Cecil, Meredith Slota, Megan M. O’Meara, (unknown), Ekram Gad, Yushe Dang, Daniel R. Herendeen, (unknown), Mary L. Disis	29
12	Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer 2016 ·Seminars in Immunopathology ·W. C. Watt, Denise L. Cecil, Mary L. Disis	17
13	Preservation of tumor-host immune interactions with luciferase-tagged imaging in a murine model of ovarian cancer 2015 ·Journal for ImmunoTherapy of Cancer ·John B. Liao, (unknown), (unknown), Denise L. Cecil, (unknown), (unknown), Ekram Gad, Mary L. Disis	23
14	Elimination of IL-10–Inducing T-Helper Epitopes from an IGFBP-2 Vaccine Ensures Potent Antitumor Activity 2014 ·Cancer Research ·Denise L. Cecil, Gregory E. Holt, Kyong Hwa Park, Ekram Gad, (unknown), Jennifer S. Childs, Doreen M. Higgins, Mary L. Disis	38
15	A Multiantigen Vaccine Targeting Neu, IGFBP-2, and IGF-IR Prevents Tumor Progression in Mice with Preinvasive Breast Disease 2013 ·Cancer Prevention Research ·Mary L. Disis, Ekram Gad, Daniel R. Herendeen, (unknown), Kyong Hwa Park, Denise L. Cecil, Megan M. O’Meara, Piper M. Treuting, Ronald A. Lubet	59
16	T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity 2013 ·Breast Cancer Research and Treatment ·Denise L. Cecil, Kyong Hwa Park, Ekram Gad, Jennifer S. Childs, Doreen M. Higgins, Stephen R. Plymate, Mary L. Disis	15
17	Arterial Calcification Is Driven by RAGE in <i>Enpp1</i>–/– Mice 2010 ·Journal of Vascular Research ·Denise L. Cecil, Robert Terkeltaub	33
18	Preventing the Development of Breast Cancer by Immunizing with Multi-Antigen Vaccines Targeting Proteins Associated with Oncogenesis. 2009 ·Cancer Research ·Mary L. Disis, Denise L. Cecil, Ekram Gad, (unknown), (unknown), Ronald A. Lubet, Hailing Lu	1
19	Inflammation-Induced Chondrocyte Hypertrophy Is Driven by Receptor for Advanced Glycation End Products 2005 ·The Journal of Immunology ·Denise L. Cecil, Kristen Johnson, John Rediske, Martin Lotz, Ann Marie Schmidt, Robert Terkeltaub	137
20	Role of interleukin‐8 in PiT‐1 expression and CXCR1‐mediated inorganic phosphate uptake in chondrocytes 2005 ·Arthritis & Rheumatism ·Denise L. Cecil, David M. Rose, Robert Terkeltaub, Ru Liu‐Bryan	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact